Kane Biotech Advances with DispersinB Acne Clinical Trial
WINNIPEG, Manitoba — Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) proudly announces its recent approval from the Internal Review Board (IRB) at the University of Miami Health System for the launch of a groundbreaking clinical study. This study will investigate the efficacy of the innovative DispersinB Acne Cleanser in treating mild to moderate cases of Acne Vulgaris.
Details of the Clinical Study
Titled "Split-face efficacy and tolerability of DispersinB Acne Cleanser in the treatment of mild to moderate Acne Vulgaris," this clinical trial aims to assess how well the cleanser performs among up to 24 participants. The trial is set to take place at the distinguished University of Miami Miller School of Medicine, renowned for its expertise in dermatology.
Significance of the Study
This clinical trial represents a milestone for Kane Biotech, signaling a major step forward in the quest to improve treatment options for those suffering from acne. Marc Edwards, President & CEO of Kane Biotech, expressed his enthusiasm, stating, "DispersinB stands to be a revolutionary approach that could significantly benefit millions affected by this skin condition. This approval is a testament to our dedication to pioneering science-backed dermatological solutions.
About Kane Biotech
Kane Biotech Inc. is a prominent player in the biotechnology sector, specializing in the research, development, and commercialization of cutting-edge technologies designed to prevent and eliminate microbial biofilms. With a robust intellectual property portfolio featuring 66 patents, Kane continues to grow its expertise in biofilm management through its extensive research initiatives. Products like DispersinB and innovations such as coactiv+, DermaKB, and revyve highlight the company’s commitment to health and wellness.
The Company’s Vision
Kane aims to create science-driven solutions that cater to various health challenges, and the DispersinB Acne Cleanser is just one example of this mission in action. The company focuses not only on product development but also on addressing real-world health concerns through innovation and advanced research.
About the University of Miami Health System
The University of Miami Health System (UHealth) is globally recognized for delivering exceptional patient care and specializing in complex medical conditions. With nearly 40 outpatient facilities and numerous providers throughout South Florida, UHealth stands as a leader in the academic healthcare domain. Their commitment to research and patient-centered care further cements their position as a pillar of community health services.
UHealth's Contributions to Healthcare
With recognized programs such as the Bascom Palmer Eye Institute and the Sylvester Comprehensive Cancer Center, UHealth plays a critical role in promoting medical education and advancing treatment methodologies across various specialties. Their collaborative approach to healthcare leads to improved outcomes and enhanced patient experiences.
Contact Information
For further information on the clinical trial or Kane Biotech's innovations, individuals can reach out to the following:
Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
Email: medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
What is the DispersinB Acne Trial about?
The trial investigates the effectiveness of the DispersinB Acne Cleanser on mild to moderate Acne Vulgaris.
Where will the clinical trial be conducted?
The clinical trial is scheduled to take place at the University of Miami Miller School of Medicine.
How many participants will be involved in the trial?
Up to 24 participants will participate in the clinical trial.
What is the significance of this clinical trial for Kane Biotech?
This trial marks a major advancement in Kane Biotech's mission to provide innovative treatments for skin conditions.
How can I contact Kane Biotech for more information?
You can reach out to Marc Edwards at medwards@kanebiotech.com or Ray Dupuis at rdupuis@kanebiotech.com for inquiries.
